Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Pablo Banderas

Physician Assistant, Medical Cape Coral, FL Physician Assistant

NPI 1609868835 CMS profile 253772

126 Del Prado Blvd N, Ste 104, Cape Coral, FL 33909

Open in the dashboard

General payments

$27,082

1,135 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pablo Banderas of Cape Coral, FL is reported in the CMS Open Payments database as having received $27,082 across 1,135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,080 159
2024 General $5,003 191
2023 General $6,113 253
2022 General $5,488 225
2021 General $6,398 307

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pablo Banderas
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Pablo Banderas were reported at $4,080. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Pablo Banderas Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $6,398 $156 $41–$563 $132
2022 $5,488 $185 $55–$649 $149
2023 $6,113 $199 $58–$717 $160
2024 $5,003 $206 $62–$740 $164
2025 $4,080 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,729 73 payments
  2. Amgen Inc. $2,408 109 payments
  3. AbbVie, Inc. $2,330 94 payments
  4. GlaxoSmithKline, LLC. $1,466 74 payments
  5. Janssen Pharmaceuticals, Inc $1,348 37 payments
  6. Lilly USA, LLC $1,346 58 payments
  7. Novo Nordisk Inc $1,244 68 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $1,239 38 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $1,153 20 payments
  10. ITI, Inc. $1,038 44 payments
  11. Other $10,782 520 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $26,261 1,132 payments
  2. Consulting Fee $800 1 payment
  3. Education $12 1 payment
  4. Travel and Lodging $10 1 payment
Products named General payments · program years 2021–2025
  1. BREZTRI $1,547 27 payments
  2. NURTEC ODT $1,394 29 payments
  3. XARELTO $1,327 36 payments
  4. TRELEGY ELLIPTA $1,240 63 payments
  5. Kerendia $1,239 38 payments
  6. Otezla $1,126 52 payments
  7. Ozempic $1,089 58 payments
  8. UBRELVY $1,063 36 payments
  9. AIRSUPRA $1,050 23 payments
  10. RYBELSUS $1,029 55 payments
  11. Other $22,368 1,068 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 128 drugs

Part D claims

6,570

Median for Physician Assistant: 241

Drug cost

$689,695

Median for Physician Assistant: $4,110

Branded share of claims

17.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 131 $146,794
Jardiance Empagliflozin Brand 97 $105,270
Farxiga Dapagliflozin Propanediol Brand 57 $56,133
Eliquis Apixaban Brand 44 $36,928
Xarelto Rivaroxaban Brand 42 $35,874
Caplyta Lumateperone Tosylate Brand 14 $26,699
Rybelsus Semaglutide Brand 17 $24,775
Vascepa Icosapent Ethyl Brand 22 $20,854
Linzess Linaclotide Brand 20 $19,413
Kerendia Finerenone Brand 24 $19,116

The 10 drugs with the highest cost, of 128 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$39,553

Of which drugs: $811

Medicare patients

161

Average age 76

Services billed

2,038

73 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Chronic kidney disease 43%
Diabetes 36%
Ischemic heart disease 35%
Depression 27%
Heart failure 23%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
$618 42 —
AIRSUPRA
$426 — —
Otezla
$390 — —
GEMTESA
$227 19 —
UBRELVY
$224 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

1,135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record